<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cardiovasc Magn Reson</journal-id><journal-id journal-id-type="iso-abbrev">J Cardiovasc Magn Reson</journal-id><journal-title-group><journal-title>Journal of Cardiovascular Magnetic Resonance</journal-title></journal-title-group><issn pub-type="ppub">1097-6647</issn><issn pub-type="epub">1532-429X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4328619</article-id><article-id pub-id-type="publisher-id">4319</article-id><article-id pub-id-type="doi">10.1186/1532-429X-17-S1-P191</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Cardiovascular Magnetic Resonance GUIDEd management of mild-moderate left ventricular systolic Heart Failure (CMR GUIDE HF): study protocol for a randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Selvanayagam</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="Aff27"/><xref ref-type="aff" rid="Aff28"/></contrib><contrib contrib-type="author"><name><surname>Prasad</surname><given-names>Sanjay K</given-names></name><xref ref-type="aff" rid="Aff30"/></contrib><contrib contrib-type="author"><name><surname>McGavigan</surname><given-names>Andrew D</given-names></name><xref ref-type="aff" rid="Aff27"/></contrib><contrib contrib-type="author"><name><surname>Hillis</surname><given-names>Graham</given-names></name><xref ref-type="aff" rid="Aff29"/></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>Werner</given-names></name><xref ref-type="aff" rid="Aff31"/></contrib><contrib contrib-type="author"><name><surname>Krum</surname><given-names>Henry</given-names></name><xref ref-type="aff" rid="Aff32"/></contrib><aff id="Aff27"><label/>Flinders Medical Centre, Bedford Park, SA Australia </aff><aff id="Aff28"><label/>Flinders University, Adelaide, SA Australia </aff><aff id="Aff29"><label/>Sydney University, Sydney, NSW Australia </aff><aff id="Aff30"><label/>Royal Brompton Hospital, London, UK </aff><aff id="Aff31"><label/>Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany </aff><aff id="Aff32"><label/>Monash University, Melbourne, VIC Australia </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>17</volume><issue>Suppl 1</issue><elocation-id>P191</elocation-id><permissions><copyright-statement>&#x000a9; Selvanayagam et al; licensee BioMed Central Ltd. 2015</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Current heart failure guidelines recommend insertion of implantable cardiac defibrillators (ICD) for primary prevention of sudden cardiac death (SCD) in patients whose left ventricular ejection fraction is (LVEF) &#x02264; 35% on maximally tolerated medical therapy. However, the majority of sudden cardiac death (SCD) in patients with heart failure occurs in those with mild-moderate systolic heart failure (LVEF 36%-50%) who currently do not qualify for an ICD. At present, our tools to reliably risk stratify patients with mild-moderate heart failure to predict the likelihood of SCD are limited. Recent data however suggest that ventricular scar and/or replacement fibrosis, reliably identified on Cardiac Magnetic Resonance Imaging (CMR), forms a substrate for malignant arrhythmia, thus potentially identifying a group at increased risk of SCD. The <bold>primary aim</bold> of the <bold>C</bold>ardiovascular <bold>M</bold>agnetic <bold>R</bold>esonance <bold>GUIDE</bold>d management of mild-moderate left ventricular systolic <bold>H</bold>eart <bold>F</bold>ailure (CMR GUIDE HF) trial is to test the hypothesis that among patients with mild-moderate heart failure, a routine CMR guided management strategy of implantable defibrillator (ICD) insertion is superior to a conservative strategy of standard care.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><p>A multi-centre randomized control trial based in Australia and Europe, enrolling 428 patients with mild to moderate left ventricular systolic dysfunction, on optimal heart failure therapy. Participants will be recruited through heart failure clinics and echocardiography databases to undergo CMR assessment for myocardial scar and fibrosis. The study will have two arms: Firstly, those with myocardial scar/fibrosis will be enrolled into a prospective, blocked, randomized control trial to receive either primary prophylaxis ICD therapy or an implantable loop recorder (ILR). Secondly, a further 521 patients without scar/fibrosis will be enrolled into an observational registry. Follow-up with be at 3, 6, 12, 24 and 36 months for the implant groups (ICD and ILR) and at 12, 24 and 36 months for the registry group.</p></sec><sec id="Sec3" sec-type="results"><title>Results</title><p>The primary endpoint will be time to sudden cardiac death, or syncopal ventricular arrhythmia during an average 3-year follow-up. The secondary endpoints consist of sudden cardiac death, syncopal ventricular arrhythmia, all-cause mortality, quality of life assessed by Minnesota Living with Heart Failure Questionnaire, heart failure related hospitalizations and a cost utility analysis.</p></sec><sec id="Sec4" sec-type="conclusions"><title>Conclusions</title><p>This study will use <bold>CMR as a novel tool for risk stratification</bold> by directly imaging the scar which forms a critical substrate for ventricular arrhythmia. The results of this study will result in a <bold>highly significant advance in knowledge in this field</bold> by providing new information about the potential benefits of primary prevention ICD in mild-moderate LV systolic dysfunction. If proven, it would radically alter the way in which patients are selected for ICD therapy.</p></sec><sec id="Sec5"><title>Funding</title><p>Biotronik Australia.</p><p>NHMRC Govt of Australia.<fig id="Fig1"><caption><p>Figure 1</p></caption><graphic xlink:href="12968_2015_4319_Fig1_HTML" id="d30e276"/></fig></p></sec></body></article>